Bioporto A/S
OTC:THOXF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bioporto A/S
Revenue
Bioporto A/S
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bioporto A/S
CSE:BIOPOR
|
Revenue
kr40.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
|
Genmab A/S
CSE:GMAB
|
Revenue
kr3.7B
|
CAGR 3-Years
22%
|
CAGR 5-Years
19%
|
CAGR 10-Years
36%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Revenue
kr9.2B
|
CAGR 3-Years
346%
|
CAGR 5-Years
117%
|
CAGR 10-Years
48%
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Revenue
€720.1m
|
CAGR 3-Years
141%
|
CAGR 5-Years
153%
|
CAGR 10-Years
57%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Revenue
kr6.2B
|
CAGR 3-Years
26%
|
CAGR 5-Years
28%
|
CAGR 10-Years
20%
|
|
Bioporto A/S
Glance View
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
See Also
What is Bioporto A/S's Revenue?
Revenue
40.3m
DKK
Based on the financial report for Dec 31, 2025, Bioporto A/S's Revenue amounts to 40.3m DKK.
What is Bioporto A/S's Revenue growth rate?
Revenue CAGR 10Y
7%
Over the last year, the Revenue growth was 11%. The average annual Revenue growth rates for Bioporto A/S have been 12% over the past three years , 12% over the past five years , and 7% over the past ten years .
